Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 259 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Midazolam 2 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Study of Qualaquin and Midazolam

NCT00785486
View directory record Official record
Conditions
Healthy
Interventions
Midazolam Alone, Qualaquin (quinine) alone steady state, Midazolam and Qualaquin at steady state
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Not applicable Interventional Results available

Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy

NCT01769586
View directory record Official record
Conditions
Sedation, Endoscopy
Interventions
Diphenhydramine, Midazolam
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 23, 2026, 4:51 AM EDT
Recruiting Phase 3 Interventional

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

NCT05646862
View directory record Official record
Conditions
Breast Cancer
Interventions
Inavolisib, Fulvestrant, Alpelisib, Bupropion, Omeprazole, Midazolam
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
39
States / cities
Greenbrae, California • Los Alamitos, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

NCT06704763
View directory record Official record
Conditions
Healthy
Interventions
Orforglipron, Midazolam, Quinidine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
21 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects

NCT01757756
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
Pf-05175157, placebo, midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2012 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 2 Interventional

Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS

NCT00579085
View directory record Official record
Conditions
Complex Regional Pain Syndrome
Interventions
Ketamine, IV NSS, Normal Saline
Drug · Other
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 17, 2010 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Not applicable Interventional Results available

Compare Propofol to Fentanyl and Midazolam for Colonoscopy

NCT01488045
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer, Colonic Diverticulosis
Interventions
Fentanyl, Propofol, Midazolam
Drug
Lead sponsor
Trinity Health Michigan
Other
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the Body

NCT04187456
View directory record Official record
Conditions
Solid Tumors
Interventions
Savolitinib, Midazolam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 2 Interventional Results available

PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery

NCT03084536
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Cancer of Breast
Interventions
Bupivacaine, Gabapentin, Celecoxib, Acetaminophen, Midazolam, Fentanyl
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 23, 2026, 4:51 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

NCT02244112
View directory record Official record
Conditions
Advanced Non-Central Nervous System (CNS) Malignancies
Interventions
Oprozomib, Midazolam
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study of ACH-0145228

NCT04709081
View directory record Official record
Conditions
Healthy
Interventions
ACH-0145228, Midazolam, Digoxin, Itraconazole
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3484356 in Healthy Female Participants

NCT04840888
View directory record Official record
Conditions
Healthy
Interventions
LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

NCT01585623
View directory record Official record
Conditions
Solid Tumor
Interventions
SAR302503, omeprazol, metoprolol, midazolam
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Augusta, Georgia • Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ketamine for Treatment of MS Fatigue

NCT03500289
View directory record Official record
Conditions
Multiple Sclerosis, Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

NCT01140607
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
Cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
14
States / cities
La Jolla, California • Loma Linda, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2015 · Synced Oct 23, 2026, 4:51 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

The RECAP2 Study: Midazolam and Psilocybin

NCT06692192
View directory record Official record
Conditions
Psilocybin
Interventions
Psilocybin, Midazolam, Saline
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers

NCT02140268
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam, AZD1722, AZD1722 and Midazolam
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 50 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2015 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

NCT01442532
View directory record Official record
Conditions
Healthy Male Volunteer
Interventions
JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Potential CYP3A4 Induction by INDV-2000 in Healthy Adults

NCT05694533
View directory record Official record
Conditions
Healthy
Interventions
INDV-2000, Midazolam
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 23, 2026, 4:51 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

NCT03358706
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis
Interventions
Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
3
States / cities
Cypress, California • Miami Springs, Florida • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Midazolam Effect in Children Undergoing Voiding Cystourethrogram (VCUG)

NCT00894465
View directory record Official record
Conditions
Vesicoureteral Reflux
Interventions
midazolam, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
2 Years to 6 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

NCT06227832
View directory record Official record
Conditions
Healthy Adults
Interventions
KP-001, Metformin, Midazolam, Clarithromycin
Drug
Lead sponsor
Kaken Pharmaceutical
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants

NCT07190430
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820, Midazolam, Dabigatran Etexilate, Portia (EE and LN) or equivalent oral tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 23, 2026, 4:51 AM EDT
Completed Phase 4 Interventional Results available

Evaluation of Oral Midazolam in First-trimester Surgical Abortions

NCT01830881
View directory record Official record
Conditions
Pain, Anxiety, Nausea
Interventions
Midazolam, Ibuprofen, Placebo-Cherry syrup, Lidocaine
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 23, 2026, 4:51 AM EDT